Literature DB >> 30325179

Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis.

T Vanbrabant1, M Fassnacht2,3,4, G Assie5,6, O M Dekkers1,7.   

Abstract

Objective Adrenocortical carcinoma (ACC) is a malignancy with a poor prognosis. Many publications in ACC report on risk factors for a poor outcome; one risk factor studied is hormonal hypersecretion (cortisol, sex-hormones, steroid precursors or aldosterone). The aim of this systematic review was to study the association between hormonal secretion and recurrence or mortality in ACC. Design Systematic review and meta-analysis. We searched PubMed, EMBASE and The Cochrane library (January 2018) for cohort studies examining the association between hormonal secretion on overall or recurrence-free survival in ACC. Methods A random-effects model meta-analysis was performed to obtain a weighted relative risk comparing cortisol-secreting and/or androgen-secreting ACCs to non-secreting tumours regarding overall and recurrence-free survival. Risk of bias assessment was performed for all studies included. Results Nineteen publications were included representing a total of 3814 patients. Most studies were generally considered low/intermediate risk of bias. Meta-analysis showed higher mortality risk for cortisol-secreting ACCs, weighted relative risk 1.71 (95% CI: 1.18-2.47) combining studies that adjusted for tumour stage; also a higher recurrence risk was found for cortisol producing ACCs, relative risk 1.43 (95% CI: 1.18-1.73). Androgen secretion was not clearly associated with survival (RR: 0.82, 95% CI: 0.60-1.12). Conclusion This systematic review and meta-analysis show that cortisol-secreting ACCs are associated with a worse overall survival; future research is needed to establish whether this association points to negative effects of cortisol action, whether it signifies a more aggressive ACC subtype or whether cortisol is merely a prognostic marker.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30325179     DOI: 10.1530/EJE-18-0450

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  23 in total

1.  Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Possible Prognostic Markers for Patients Undergoing Resection of Adrenocortical Carcinoma.

Authors:  Mechteld C de Jong; Radu Mihai; Shahab Khan
Journal:  World J Surg       Date:  2020-11-21       Impact factor: 3.352

Review 2.  Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma.

Authors:  Michael R Clay; Emilia M Pinto; Lauren Fishbein; Tobias Else; Katja Kiseljak-Vassiliades
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

3.  Tumour size in adrenal tumours: its importance in the indication of adrenalectomy and in surgical outcomes-a single-centre experience.

Authors:  C Mínguez Ojeda; V Gómez Dos Santos; J Álvaro Lorca; I Ruz-Caracuel; H Pian; A Sanjuanbenito Dehesa; F J Burgos Revilla; M Araujo-Castro
Journal:  J Endocrinol Invest       Date:  2022-06-24       Impact factor: 5.467

4.  S-GRAS score performs better than a model from SEER for patients with adrenocortical carcinoma.

Authors:  Wenhao Lin; Jun Dai; Jialing Xie; Jiacheng Liu; Fukang Sun; Xin Huang; Wei He; Chen Fang; Juping Zhao; Danfeng Xu
Journal:  Endocr Connect       Date:  2022-06-21       Impact factor: 3.221

5.  The clinical utility of 'GRAS' parameters in stage I-III adrenocortical carcinomas: long-term data from a high-volume institution.

Authors:  Jiayu Liang; Zhihong Liu; Liang Zhou; Yongquan Tang; Chuan Zhou; Kan Wu; Fuxun Zhang; Fan Zhang; Xin Wei; Yiping Lu; Yuchun Zhu
Journal:  Endocrine       Date:  2019-11-30       Impact factor: 3.633

6.  Autocrined leptin promotes proliferation of non-small cell lung cancer (NSCLC) via PI3K/AKT and p53 pathways.

Authors:  Jin Wang; Fachen Zhou; Fengzhou Li; Bing Wang; Yiying Hu; Xia Li
Journal:  Ann Transl Med       Date:  2021-04

7.  Giant androgen-producing adrenocortical carcinoma with atrial flutter: A case report and review of the literature.

Authors:  Mircea-Florin Costache; Raluca-Elena Arhirii; Simona-Juliette Mogos; Corina Lupascu-Ursulescu; Cezara-Ioana Litcanu; Adi-Ionut Ciumanghel; Catalina Cucu; Cristina-Mihaela Ghiciuc; Antoniu-Octavian Petris; Nicolae Danila
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

Review 8.  Adrenal Incidentaloma.

Authors:  Mark Sherlock; Andrew Scarsbrook; Afroze Abbas; Sheila Fraser; Padiporn Limumpornpetch; Rosemary Dineen; Paul M Stewart
Journal:  Endocr Rev       Date:  2020-12-01       Impact factor: 19.871

Review 9.  Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment.

Authors:  Omair A Shariq; Travis J McKenzie
Journal:  Ther Adv Chronic Dis       Date:  2021-07-20       Impact factor: 5.091

10.  Adrenocortical Carcinoma Steroid Profiles: In Silico Pan-Cancer Analysis of TCGA Data Uncovers Immunotherapy Targets for Potential Improved Outcomes.

Authors:  João C D Muzzi; Jessica M Magno; Milena A Cardoso; Juliana de Moura; Mauro A A Castro; Bonald C Figueiredo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-14       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.